← All companies
Viking Therapeutics, Inc.
VKTX - CIK 0001607678
Market cap$3.23 B
Rank#1747
SEC filings627
Viking Therapeutics, Inc. trades as VKTX and has a market capitalization of $3.23 B, making it the #1747 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$359.64M. This page tracks Viking Therapeutics, Inc. through 627 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$0.00FY 2025
Net income (latest FY)-$359.64MFY 2025
Operating cash flow (latest FY)-$278.69MFY 2025
Total assets (latest FY)$715.73MFY 2025
Financial performance
Key statistics
- Market cap
- $3.23 B
- Share price (derived)market cap / shares outstanding
- $27.79
- EPS (diluted)FY 2025
- $-3.19
- Shares outstandingas of 2026-04-15
- 0.12B
- Total equityas of 2026-03-31
- $501.92M
- Return on equity
- -71.7%
- Cash & equivalentsas of 2026-03-31
- $118.12M
- Stock buybacksFY 2022
- $6.79M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13G | - | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-01 |
| Proxy materials | DEFA14A | 2026-04-01 |
| Proxy statement | DEF 14A | 2026-04-01 |
| SCHEDULE 13G/A | - | 2026-03-27 |
Recent press releases
- Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 20262026-05-05
Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735
- Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update2026-04-29
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled --
- Viking Therapeutics Reports Fourth Quarter and Year-End 2025 ...
This study is fully enrolled and we look forward to announcing the results in the third quarter of 2026. We also expect to file an IND for ...
Similar companies
The largest companies sharing Viking Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is Viking Therapeutics, Inc.'s market cap?
Viking Therapeutics, Inc. (VKTX) has a market capitalization of $3.23 B as of 2026-06-10, ranking #1747 among US-listed companies.
How much revenue does Viking Therapeutics, Inc. make?
Viking Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025.
Is Viking Therapeutics, Inc. profitable?
In its latest fiscal year Viking Therapeutics, Inc. reported a net loss of $359.64M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.